Pfizer says Alzheimer’s drug trial fails

Pfizer Inc and its partner, Medivation Inc are stopping a Phase 3 trial of the Alzheimer’s disease compound, Dimebon (latrepirdine), because it didn’t achieve statistical significance for either of its two co-primary endpoints.